Actions of heparin that may affect the malignant process.
about
Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis.Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasisEarly endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells.Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.Impact of venous thromboembolism and anticoagulation on cancer and cancer survivalVenous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action.P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications.Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage.Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial.Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage.Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal veinAnti-thrombotics in thrombosis and cancer.Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung.High tPA-expression in primary melanoma of the limb correlates with good prognosis.Heparin and related drugs: beyond anticoagulant activity.Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response.Heparins attenuate cancer metastasis: are selectins the link?Tumour vasculature targeting agents in hybrid/conjugate drugs.Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cis-acting elements: altered potential of hepatocellular carcinoma heparan sulphateHeparin regulates B6FS cell motility through a FAK/actin cytoskeleton axisNovel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage.Sulfation patterns determine cellular internalization of heparin-like polysaccharides.Heparins modulate the IFN-γ-induced production of chemokines in human breast cancer cells.Does antithrombotic therapy improve survival with colorectal cancer?Heparin blocks transfer of extracellular vesicles between donor and recipient cells.Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer.Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy.Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
P2860
Q24529958-FFC05C0B-968F-4B3E-B8C7-A29E39DC743CQ24630993-7D960D0E-2C58-4404-BE0A-E82EEB0FA549Q33211600-95BBB805-DB8B-405C-A4AF-A9D85F5610D2Q33410310-F68EF75E-10ED-4ADB-9DF0-97736888BFEEQ33561203-C5BB11A0-78B9-446C-8DB0-6FBF62F4445FQ33561213-15DB3FF8-B81F-4ECA-8824-1415CEE896F8Q34222480-A4EEEB7E-7876-4F26-9A2E-9982B977510BQ34265306-E04F7DA9-ABF6-4D99-8569-AF5FE8FBB8A2Q34448852-E90AA8A2-401F-4C65-8F98-DD9F8F138320Q35852208-7C77ABC9-C92C-430A-A4C0-5553C558864AQ36025124-8933DBAA-D7C5-47CD-B873-D7F0310881CDQ36397315-101E387E-F921-4AB3-B2FC-E145DC9ABFA6Q36429503-ADC6CE93-394D-4ACF-8261-ADA6739B551CQ36644517-2FC4EB4B-9CFF-468D-8802-0B3BF8BF2319Q36692014-612C24C0-A89E-4D5A-9A21-1A4D6C2BA103Q37105310-7A68EF9D-102D-4D0B-8A5A-96A0470B5BADQ37429687-2F6F2D69-126C-4668-BC0D-8C1FE7AE60A7Q37500092-0DF4C53A-C0AF-44E9-B224-D59E35E27C0BQ38094627-145C189A-2445-4098-8983-962EEFD5BB0AQ38309783-020D3EE1-170E-4B41-801D-1EE7FB16066FQ38737938-EC483631-B7B8-48D7-9079-844994690B90Q38871467-186C0B92-D6C9-4399-9D4A-97632286FD71Q39196713-83F95D09-9D0E-48E0-8C43-36B4C3B1A517Q39243093-B72BBFDF-BB4F-499F-9BD3-3083C579E8DDQ41521182-4E18AAE7-12D4-46E6-8267-A1E86EF889C5Q42114560-D83961C2-1360-4CAB-9792-532DFBD7BC8AQ42317502-C870C2BF-2BDE-46D0-ADE3-DFCF5557FFCCQ45714368-D7AC34E7-777C-4FD5-B99E-940943470BCBQ58693989-6E9D6957-FA23-40D3-AD60-13647BFA65DB
P2860
Actions of heparin that may affect the malignant process.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Actions of heparin that may affect the malignant process.
@ast
Actions of heparin that may affect the malignant process.
@en
Actions of heparin that may affect the malignant process.
@nl
type
label
Actions of heparin that may affect the malignant process.
@ast
Actions of heparin that may affect the malignant process.
@en
Actions of heparin that may affect the malignant process.
@nl
prefLabel
Actions of heparin that may affect the malignant process.
@ast
Actions of heparin that may affect the malignant process.
@en
Actions of heparin that may affect the malignant process.
@nl
P2860
P1433
P1476
Actions of heparin that may affect the malignant process.
@en
P2093
Engelberg H
P2860
P304
P356
10.1002/(SICI)1097-0142(19990115)85:2<257::AID-CNCR1>3.0.CO;2-2
P407
P577
1999-01-01T00:00:00Z